摘要
地西他滨是目前治疗骨髓增生异常综合征(MDS)的优先用药,但其在中国尚未展开大规模的临床应用,其应用于中国人的疗效及安全性尚未评估。我院对1例MDS患者进行了地西他滨第1个疗程的治疗,取得满意疗效,提示地西他滨在中国具有良好的应用前景。
Decitabine is now recommended for the treatment of myelodysplastic syndrome （MDS）, but its largescale clinical application has not been carried out in China, its efficacy and safety have not been assessed for the Chinese people. We took the first course of decitabine treatment on one patient with MDS, and the efficacy is satisfactory. Revealed that in China, decitabine may has a good application prospects.
出处
《现代医学》
2010年第2期189-190,共2页
Modern Medical Journal
